The contribution of animal models to the development of treatments for hematologic recovery following myeloablative therapy: a review.
This review describes the role that animal models have played in the development of clinical procedures for growth factor and hematopoietic cell therapies following high-dose cancer chemotherapy, radiotherapy or both. Data are discussed describing animal models that add to the understanding of human hematopoiesis, including myeloid and lymphoid lineage localization and in vivo maturation. Finally, current animal models of cytokine and cell therapies are presented in the context of their contributions to early clinical trials and future therapies. These studies underscore the past and current contributions animal investigations have made to improving clinical therapies.
Schneidkraut
M J
MJ
Baxter Healthcare Corporation, Biotech Group, Immunotherapy Division, Irvine, CA 92618, USA.
Hangoc
G
G
Bender
J G
JG
Huntenburg
C C
CC
D000818:Animals; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D006410:Hematopoiesis; D016298:Hematopoietic Cell Growth Factors; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009374:Neoplasms, Experimental / Q000628:therapy*; D019172:Transplantation Conditioning
D016298:Hematopoietic Cell Growth Factors